Table of Contents
Introduction
Global Neurostimulation Devices Market size is expected to be worth around US$ 36.5 Billion by 2032 from US$ 12.5 Billion in 2023, growing at a CAGR of 13% during the forecast period from 2023 to 2032. In 2023, North America led the market, achieving over 50% share with a revenue of US$ 5.5 Billion.
This market expansion is driven by continuous advancements in neurotherapy, which have shown substantial potential in addressing a wide range of neurological and psychiatric disorders. Neurostimulation devices are increasingly recognized for their effectiveness in reducing symptoms such as pain, fatigue, depression, and sleep disturbances commonly associated with chronic illnesses, including cancer. Moreover, these devices are being investigated for their capabilities to alleviate cognitive declines related to aging, like those observed in Alzheimer’s disease.
Deep Brain Stimulation (DBS) continues to be a critical component of the neurostimulation sector, providing essential benefits for managing conditions that are less responsive to conventional medications, such as Parkinson’s disease and severe epilepsy. DBS offers adjustable and reversible treatment options, significantly improving patients’ quality of life. Advances in surgical technologies, like image-guided and stereotactic surgeries, have notably enhanced the safety and effectiveness of these treatments.
Another groundbreaking technology in this field is Responsive Neurostimulation (RNS), which identifies abnormal brain activity and automatically delivers electrical pulses to potentially prevent seizures. Clinical trials have demonstrated a significant decrease in seizure frequency with RNS, making it a viable option for patients who are unsuitable for conventional surgery due to the risk of damaging critical brain functions.
The neurostimulation field is experiencing an increase in FDA approvals and extensive clinical trials, indicating a rising trust in these therapies as viable medical solutions. This progression highlights the sector’s growth and the broadening applications of neurostimulation devices across various neurological and psychiatric conditions. Ongoing research is expected to further confirm and extend the uses of these devices, facilitating their incorporation into standard medical practices.
Key recent developments in the industry include the FDA’s approval of Medtronic’s Inceptiv closed-loop spinal cord stimulator in April 2024, a significant innovation that adjusts stimulation automatically. Moreover, Boston Scientific Corporation’s acquisition of Axonics, Inc. for $3.7 billion in January 2024 marks a strategic move into urology and neurostimulation therapies.
Additionally, in August 2023, Nevro’s strategic collaboration with Boston Scientific, worth $75 million, aims to enhance the global availability of sophisticated pain management solutions. These strategic activities underscore the market’s dynamic nature and anticipate continued innovation and growth within the neurostimulation sphere.
Key Takeaways
- In 2022, the global neurostimulation devices market was valued at US$ 11.1 billion and is expected to grow at a 13% CAGR until 2032.
- Spinal cord stimulators led the 2022 market with a 51% share, primarily used for managing chronic neuropathic pain.
- Deep brain stimulators are primarily utilized for treating neurological disorders, such as Parkinson’s disease.
- Sacral nerve stimulators are effective in managing conditions like fecal and urinary incontinence.
- Pain management is the leading application due to the high prevalence of chronic pain disorders.
- The treatment of epilepsy is increasing due to effective outcomes and limited alternative treatments.
- In 2022, hospitals were the leading end-users with a 34% revenue share, supported by robust healthcare infrastructure.
- Specialty clinics are expanding, increasingly gaining approval to implant neurostimulation devices.
- Market growth is driven by an aging population and technological advancements in devices like spinal cord and deep brain stimulators.
- Common market challenges include the risks associated with the surgical procedures of neurostimulation devices and stringent regulatory approvals.
- Opportunities are emerging from corporate initiatives targeting Parkinson’s disease and rapid technological progress.
- North America dominates the market with a 50% share, led by the U.S., while Europe holds a 28% share.
- The Asia-Pacific region is expected to be the fastest-growing market for neurostimulation devices.
- Key market players like Medtronic plc and Boston Scientific Corporation are heavily investing in R&D to innovate in neurostimulation systems.
Statistics For Neurostimulation Devices
- Epilepsy Treatment: 30% of epilepsy patients do not respond to conventional medications. Temporal lobe surgery helps 60% of these patients achieve freedom from disabling seizures.
- RNS System Efficacy:
- Approved by the FDA in 2013 for treating focal seizures in adults.
- Patients using the RNS System report a 67% reduction in seizures after one year.
- Seizure reduction increases to 75% after two years and 82% after three or more years with the system.
- After two years, 77% of users experience a seizure reduction of at least 50%.
- One-third of users report no seizures for six consecutive months during long-term studies.
- A study involving 191 participants noted improvements in physical and cognitive health, independent of seizure reduction.
- Nalu Neurostimulation System Results:
- Delivers over 50% pain relief to 87% of its users.
- Users report an average pain reduction of 73% after 12 months.
- 98% of users report significant pain relief or improvement within three months.
- In contrast, only 21% of individuals in a non-Nalu control group report significant pain relief over the same period.
- 93% of Nalu PNS users achieve more than 50% pain relief or reduced disability, compared to 35% in the control group.
- Transcranial Magnetic Stimulation (TMS) Outcomes:
- 39% of patients using real TMS achieve pain freedom, compared to 22% with sham treatment.
- 29% of real TMS users maintain pain freedom, versus 16% in the sham group.
- 27% of real TMS users continue to be pain-free, compared to 13% in the sham group.
- Single-Pulse Transcranial Magnetic Stimulation (sTMS) for Migraine Relief:
- 62% of participants in a UK pilot program find sTMS effective in reducing or alleviating migraine headaches.
- 59% experience a decrease in the number of headache days after 12 weeks of using the sTMS device.
- However, 55% of patients discontinue using the sTMS device, likely due to dissatisfaction.
Emerging Trends in Neurostimulation Devices
- Technological Advancements: The neurostimulation devices sector is witnessing significant technological progress, which is improving the safety and efficacy of treatments. These innovations focus on precise neural targeting and the development of minimally invasive procedures, reducing recovery times and enhancing patient outcomes by making treatments less intrusive and more precise.
- Expansion into New Medical Areas: Neurostimulation devices are being increasingly utilized beyond traditional uses like pain management. They are now being explored for treating conditions such as urinary and fecal incontinence, depression, and Alzheimer’s disease, showcasing the versatile benefits these devices offer across various medical fields.
- Integration with Artificial Intelligence (AI): AI is playing a crucial role in advancing neurostimulation devices. Its ability to analyze brain activity and adjust stimulation parameters in real-time fosters more personalized treatments. This integration not only boosts the effectiveness of treatments but also enhances ongoing patient monitoring, making treatments more adaptive and responsive.
- Cost Reduction Efforts: The industry is making concerted efforts to lower the costs of neurostimulation devices through cost-effective manufacturing techniques and models that reduce the need for expensive maintenance or replacements. Lowering costs makes these devices more accessible to a wider patient population, promoting healthcare inclusivity.
- Regulatory Advancements: As neurostimulation devices break into new therapeutic areas, regulatory frameworks are adapting to expedite safe and swift market introductions. Streamlined approval processes are being established to match the pace of technological innovations, ensuring new devices are safe and quickly available to patients.
Use Cases of Neurostimulation Devices
- Chronic Pain Management: These devices offer significant relief for individuals with chronic pain where traditional treatments have failed. By disrupting pain signals to the brain, they provide a non-pharmacological form of relief, which is a long-term solution for managing chronic pain symptoms.
- Parkinson’s Disease: Deep Brain Stimulators are revolutionizing the treatment of Parkinson’s disease, significantly reducing symptoms like tremors and stiffness, thus improving patients’ quality of life. By stimulating specific brain areas, these devices help alleviate the physical disruptions associated with Parkinson’s.
- Epilepsy Management: For patients unresponsive to medication, neurostimulation offers a promising alternative. These devices preemptively interrupt seizures by delivering targeted electrical impulses, effectively controlling seizures and enhancing the life quality for those affected.
- Depression: Vagus Nerve Stimulation (VNS) is emerging as an effective treatment for severe depression, especially in patients unresponsive to traditional therapies. VNS sends mild electric pulses to the brain via the vagus nerve, influencing mood centers and offering new hope for recovery.
- Urinary and Fecal Incontinence: Neurostimulation has shown effectiveness in managing urinary and fecal incontinence through sacral nerve stimulation, particularly for patients who have not benefited from conventional treatments. This method significantly reduces incontinence episodes, improving patients’ quality of life and confidence.
Conclusion
The neurostimulation devices market is rapidly expanding, driven by advancements in technology, increasing FDA approvals, and growing applications across various medical fields. These devices effectively address chronic pain, neurological disorders, and psychiatric conditions, offering non-invasive and personalized treatment options. Innovations like Deep Brain Stimulation (DBS), Responsive Neurostimulation (RNS), and Transcranial Magnetic Stimulation (TMS) are transforming patient care.
Efforts to reduce costs and integrate artificial intelligence further enhance accessibility and treatment efficiency. With increasing global demand, supported by robust research, the market is poised for sustained growth, cementing neurostimulation devices as a critical component of modern medical treatment protocols.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
